Cite
Khedr F, Ibrahim MK, Eissa IH, et al. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. Arch Pharm (Weinheim). 2021;354(11):e2100201doi: 10.1002/ardp.202100201.
Khedr, F., Ibrahim, M. K., Eissa, I. H., Abulkhair, H. S., & El-Adl, K. (2021). Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. Archiv der Pharmazie, 354(11), e2100201. https://doi.org/10.1002/ardp.202100201
Khedr, Fathalla, et al. "Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations." Archiv der Pharmazie vol. 354,11 (2021): e2100201. doi: https://doi.org/10.1002/ardp.202100201
Khedr F, Ibrahim MK, Eissa IH, Abulkhair HS, El-Adl K. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. Arch Pharm (Weinheim). 2021 Nov;354(11):e2100201. doi: 10.1002/ardp.202100201. Epub 2021 Aug 19. PMID: 34411344.
Copy
Download .nbib